Metformin and COVID‐19: A novel deal of an old drug
Abstract
In 2002, China witnessed the emergence of a severe acute respiratory disease caused by coronavirus SARS-CoV. Ten years later in 2012 a new version of the virus appeared in the Middle East known as Middle East Respiratory Syndrome Coronavirus MERS-CoV. At the end of 2019, the Chinese Center for Disease Control and Prevention (China CDC) recorded a pneumonia of unknown causes. Epidemiologically, the pneumonia was linked to a wet animal and seafood wholesale market in Wuhan, Hubei Province, China, later Known by COVID-19. The COVID-19 is a global pandemic infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1. Till now the total number of confirmed cases is 2,709,483 in over 225 countries around the world. A recent report indicates that obesity may responsible for increasing the mortality of COVID-19 in Italy rather than in China 2. Here we would like to shed light on a new suggestion to decrease the mortality rate of COVID-19. This article is protected by copyright. All rights reserved.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.